Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. HCC occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. In the US, incidence rates of HCC per 100,000 persons are 13.6 in men and 4.7 in women.
A clinical trial evaluated the effectiveness of a drug called sorafenib plus hepatic arterial infusion chemotherapy in HCC patients with portal vein thrombosis.
HCC is a type of liver cancer that can be very difficult to treat, especially when it has spread to other parts of the body. One of the ways in which HCC can spread is through the portal vein, which is a large blood vessel that carries blood from the intestines to the liver. When HCC spreads to the portal vein, it can form a clot, which is called portal vein tumor thrombosis (PVTT).
Sorafinib is a drug commonly used to treat advanced HCC. It is a type of targeted therapy that can help to slow the growth of cancer cells. However, the prognosis of hepatocellular carcinoma with major portal vein tumor thrombosis is dismal after standard treatment with sorafenib. Hepatic arterial infusion chemotherapy (HAIC) has been suggested for patients with HCC and major PVTT. It is a type of chemotherapy that is delivered directly to the liver, which can help to target the cancer cells more effectively.
Clinical TrialThe trial looked at two different treatment options for patients with HCC and PVTT. It compared the use of sorafenib plus hepatic arterial infusion chemotherapy (HAIC) with sorafenib alone.
The clinical trial involved 64 patients with HCC and PVTT who were randomly assigned to receive either sorafenib plus HAIC or sorafenib alone. The outcomes to be measured were overall survival, objective response rate, progression-free survival, and safety.